Status:
COMPLETED
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
Lead Sponsor:
Daiichi Sankyo
Conditions:
Essential Hypertension
Eligibility:
All Genders
30-70 years
Phase:
PHASE4
Brief Summary
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of...
Eligibility Criteria
Inclusion
- Stage 1 and 2 hypertension without treatment for at least 2 weeks
- Women with no risk of becoming pregnant
Exclusion
- Study participation could result in risk to health of subject
- Cardiovascular disease
- Secondary hypertension or stage 3 hypertension
- Myocardial infarction within the last 6 months
- Congestive heart failure
- Pulmonary edema
- Valvular alterations or rheumatic cardiopathy
- Clinically relevant conduction disorders significant arrhythmias
- Alcohol or illicit drug use
- Medication abuse
- Pregnant or nursing women
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00890591
Start Date
August 1 2006
End Date
August 1 2007
Last Update
June 3 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.